NCT02505568View on ClinicalTrials.gov

A Study to Evaluate Efficacy and Safety of Infliximab in Participant With Moderate-to-Severe Refractory Intestinal Behcet's Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

July 22, 2015

Primary Completion Date

July 13, 2018

Study Completion Date

July 13, 2018

Conditions
Behcet Disease
Interventions
DRUG

Infliximab

Participants will receive infliximab 5 milligram per kilogram (mg/kg) infusion at Week 0, Week 2, and Week 6 for the induction phase. Participants who complete the induction phase will continuously receive 5 mg/kg infliximab infusion every 8 weeks up to week 32 in the maintenance phase.

Trial Locations (5)

Unknown

Busan

Daegu

Gangwon-do

Gyeonggi-do

Seoul

All Listed Sponsors
lead

Janssen Korea, Ltd., Korea

INDUSTRY

NCT02505568 - A Study to Evaluate Efficacy and Safety of Infliximab in Participant With Moderate-to-Severe Refractory Intestinal Behcet's Disease | Biotech Hunter | Biotech Hunter